Concise guidance notes and market signals across ASEAN and Asian health authorities — linked from country pages for faster SEO freshness.
· Singapore
On 28 August 2026 HSA announced a Registration Support Initiative to move clinically important unregistered devices from the Special Access Route onto formal registration.
· Malaysia
On 26 August 2026 NPRA posted a Ministry of Health media statement dated 24 August 2026 on cosmetics found to contain scheduled poisons.
· Indonesia
On 24 August 2026 BPOM announced Regulation No. 11 of 2026 on food packaging, covering migration limits, permitted food-contact substances and reusable packaging.
· Philippines
On 12 August 2026 the Philippine FDA issued Advisory No. 2026-0879 warning against purchase and use of the unauthorized cosmetic Kevin & Coco Juicy Lip Gloss.
· Taiwan
On 25 August 2026 TFDA announced that from 1 October 2026 device registration, variation and extension filings will use online review with originals kept on file, and paper label approvals will stop.
· Thailand
On 8 August 2026 the Thai FDA announced a voluntary measure for nitrite-mixed salt sold to food preparers: add a pink colour and a red warning on the label, ahead of a draft legal requirement.
· Singapore
On 1 July 2026 HSA opened a stakeholder consultation on moving complementary health products under the Health Products Act, with comments due by 29 July 2026.
· Malaysia
NPRA posted on 16 July 2026 a directive dated 10 July 2026 requiring use of the Drug Registration Guidance Document, Third Edition, 12th Revision July 2026.
· Indonesia
On 13 July 2026 BPOM reported 14 cosmetics from second-quarter surveillance that contained hazardous or prohibited substances, including products with no marketing authorization.
· Philippines
On 23 July 2026 the Philippine FDA listed Administrative Order 2026-0011, revising adoption of the Codex General Standard for Food Additives and processing aids and repealing AO 88-A s. 1984.
· Taiwan
On 23 July 2026 TFDA announced a risk-evaluation and control plan for products containing semaglutide or tirzepatide, with a three-month deadline for current license holders.
· Thailand
On 14 July 2026 the Thai FDA reported that it is undergoing a PIC/S reassessment to maintain membership, covering the inspectorate, laboratory and observed GMP inspections.
